Last updated: February 21, 2026
What is the Drug Associated with NDC 00480-8722?
NDC 00480-8722 corresponds to VIBATIV (telavancin), an antibiotic used to treat complicated skin and soft tissue infections, as well as hospital-acquired pneumonia, including ventilator-associated pneumonia.
Market Overview
Market Size and Growth Prospects
- Global Antibiotics Market: Estimated at USD 49 billion in 2022, projected to grow at a CAGR of 3.8% through 2027.[1]
- Hospital-Used Antibiotics: Account for approximately 60% of antibiotics, with high constraint on resistant infections.
- Telavancin Positioning: Approved by the FDA in 2014, with a known niche in MRSA and resistant Gram-positive infections.
Competitive Landscape
- Key Competitors:
- Vancomycin
- Dalbavancin
- Oritavancin
- Other lipoglycopeptides
- Market share: Telavancin holds an estimated 3-5% of the inpatient MRSA treatment market (2022), largely due to its intravenous route and specific indications.[2]
Regulatory and Usage Trends
- Increased antibiotic resistance prompts higher adoption of novel agents like telavancin.
- North America dominates the market share, accounting for approximately 50%, with Europe and Asia-Pacific following.
Price Analysis
Historical Pricing Data
- Average Wholesale Price (AWP):
- US (2022): USD 950 per 750 mg vial.[3]
- Institutional Pricing:
- Negotiated rates lower; hospitals typically pay 20-30% less than AWP.
Cost Structure
- Vial Cost: USD 950 – 1,200 per vial, depending on volume and payer contracts.
- Administration: IV infusion costs vary; hospitals may charge USD 200-400 per dose for infusion services.
Reimbursement Environment
- Medicare/Medicaid: Reimburses based on average sale price (ASP) plus 6%.
- Private Payers: Negotiated rates vary; potential for higher margins due to limited competition.
Price Projections (2023-2027)
| Year |
Estimated AWP per Vial |
Assumed Discount |
Projected Institutional Price |
Notes |
| 2023 |
USD 950 – 1,200 |
20-30% |
USD 665 – 960 |
Steady demand; inflation pressures apply |
| 2024 |
USD 950 – 1,200 |
20-30% |
USD 665 – 960 |
Adoption of biosimilars unlikely |
| 2025 |
USD 950 – 1,200 |
20-30% |
USD 665 – 960 |
Competitive differentiation persists |
| 2026 |
USD 950 – 1,200 |
20-30% |
USD 665 – 960 |
Price stabilization expected |
| 2027 |
USD 950 – 1,200 |
20-30% |
USD 665 – 960 |
Potential growth in resistant infections |
Drivers of Price Trends
- Patent status: As of 2022, patent exclusivity expired; generic versions may exert downward pressure.
- Market penetration: Limited competition reduces the likelihood of significant price erosion.
- Pricing strategies: Manufacturers might maintain higher prices due to niche indications and limited alternatives.
Key Market Factors
- Resistance Patterns: Rising MRSA cases bolster telavancin's utilization.
- Regulatory Approvals: Additional indications or line extensions could expand markets.
- Generic Entry: Expected post-patent expiration, likely in 2024-2025, may drive prices down 15-20% over subsequent years.
Strategic Considerations
- Pricing flexibility: Hospital contracts and payer negotiations can influence net prices.
- Market share expansion: Clinical trials demonstrating superior efficacy could command premium pricing.
- Biosimilar impact: Entry of biosimilars or generics could accelerate price declines.
Summary
Telavancin (NDC 00480-8722) remains a niche antibiotic with stable but modest market share within the resistant Gram-positive infection space. Price levels are predominantly influenced by hospital negotiation power, resistance trends, and generic entry. Projections forecast a relatively flat price trajectory through 2027, with potential declines driven by patent expiry and market competition.
Key Takeaways
- The drug commands a typical price range of USD 665-960 per vial in institutional settings.
- Market share remains limited but resilient due to resistance issues.
- Price declines are expected after patent expiration, with generics potentially reducing prices by 15-20%.
- Competition from newer agents or biosimilars could further impact pricing.
- Growth depends heavily on resistance trends and clinical adoption.
FAQs
1. Will the price of telavancin drop significantly after patent expiry?
Yes. Generic entry typically leads to a 15-20% price reduction, depending on market dynamics.
2. How does resistance influence the market for telavancin?
An increase in resistant infections, particularly MRSA, sustains higher utilization and supports pricing stability.
3. Are there any upcoming approvals or indications that could impact price or market share?
Potential additional indications would expand use, likely supporting higher prices or market share.
4. How does telavancin compare in cost-effectiveness to other antibiotics?
It tends to be more expensive than generic vancomycin but may be justified in resistant cases where alternatives are less effective.
5. What is the outlook for biosimilar or generic versions?
Likely in 2024-2025; their impact includes potential price cuts and reduced profit margins.
References
[1] MarketWatch. (2023). Antibiotics Market Size, Share & Trends.
[2] IQVIA. (2022). US Hospital Antimicrobial Market Data.
[3] Red Book. (2022). Wholesale Acquisition Cost Data for Telavancin.
